Taurx Enters Collaborative R&D Agreement with Bayer Schering Pharma

摘要

In June 2010, WisTa Laboratories Ltd, a wholly owned subsidiary of TauRx Pharmaceuticals, announced that they had entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany, which could redefine the way Alzheimer's disease (AD) and related disorders are currently being diagnosed and treated. Through this collaboration, the two companies will develop specific markers that will aid in the diagnostics and management of Tau-protein related AD using brain-imaging technology. The diagnostics they are jointly aiming to develop will have applications in disease treatment and potentially disease prevention.